257 related articles for article (PubMed ID: 12841387)
1. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.
Suzuki R; Murata M; Kami M; Ohtake S; Asou N; Kodera Y; Tomonaga M; Masaki Y; Kusumoto S; Takeuchi J; Matsuda S; Hirai H; Yorimitsu mS; Hamajima N; Seto M; Shimoyama M; Ohno R; Morishima Y; Nakamura S
Int J Hematol; 2003 Jun; 77(5):482-9. PubMed ID: 12841387
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
Suzuki R; Ohtake S; Takeuchi J; Nagai M; Kodera Y; Hamaguchi M; Miyawaki S; Karasuno T; Shimodaira S; Ohno R; Nakamura S; Naoe T
Int J Hematol; 2010 Mar; 91(2):303-9. PubMed ID: 20111912
[TBL] [Abstract][Full Text] [Related]
3. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity.
Suzuki R; Yamamoto K; Seto M; Kagami Y; Ogura M; Yatabe Y; Suchi T; Kodera Y; Morishima Y; Takahashi T; Saito H; Ueda R; Nakamura S
Blood; 1997 Sep; 90(6):2417-28. PubMed ID: 9310493
[TBL] [Abstract][Full Text] [Related]
4. Transient myeloproliferative disorder with a CD7+ and CD56+ myeloid/natural killer cell precursor phenotype in a newborn.
Svaldi M; Moroder W; Messner H; Battisti L; Venturi R; Coser P; Mitterer M
J Pediatr Hematol Oncol; 2002; 24(5):394-6. PubMed ID: 12142790
[TBL] [Abstract][Full Text] [Related]
5. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.
Huang SY; Tang JL; Jou ST; Tsay W; Hu CH; Lin DT; Lin KS; Lin KS; Wang CH; Chen YC; Shen MC; Tien HF
Leukemia; 1999 Oct; 13(10):1506-12. PubMed ID: 10516750
[TBL] [Abstract][Full Text] [Related]
6. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia.
El-Sissy AH; El-Mashari MA; Bassuni WY; El-Swaayed AF
J Egypt Natl Canc Inst; 2006 Sep; 18(3):244-9. PubMed ID: 17671534
[TBL] [Abstract][Full Text] [Related]
7. CD7 expression in acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Cox C; Aronica G; Masi M; Bruno A; Simone MD; Buccisano F; Papa G
Leuk Lymphoma; 1995 Mar; 17(1-2):111-9. PubMed ID: 7539657
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.
Cruse JM; Lewis RE; Pierce S; Lam J; Tadros Y
Exp Mol Pathol; 2005 Aug; 79(1):39-41. PubMed ID: 16005710
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Features and Prognosis of 227 cases of Acute Myeloid Leukemia with Cross-lineage Antigen Expression].
Fang F; Zhu P; Zhang Y; Lu XZ; Dong YJ; Sun YH; Wang LH; Bu DF; Cen XN; Wang MJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):990-7. PubMed ID: 27531762
[TBL] [Abstract][Full Text] [Related]
10. Cerebellar myeloblastoma formation in CD7-positive, neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia (M1).
Hatano Y; Miura I; Horiuchi T; Hoshi N; Nanjou H; Masuda H; Miura AB
Ann Hematol; 1997 Sep; 75(3):125-8. PubMed ID: 9368483
[TBL] [Abstract][Full Text] [Related]
11. Biologic and clinical significance of CD7 expression in acute myeloid leukemia.
Saxena A; Sheridan DP; Card RT; McPeek AM; Mewdell CC; Skinnider LF
Am J Hematol; 1998 Aug; 58(4):278-84. PubMed ID: 9692390
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
13. The importance of CD7 and CD56 antigens in acute leukaemias.
Tiftik N; Bolaman Z; Batun S; Ayyildiz O; Isikdogan A; Kadikoylu G; Muftuoglu E
Int J Clin Pract; 2004 Feb; 58(2):149-52. PubMed ID: 15055863
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.
Chang H; Brandwein J; Yi QL; Chun K; Patterson B; Brien B
Leuk Res; 2004 Oct; 28(10):1007-11. PubMed ID: 15289011
[TBL] [Abstract][Full Text] [Related]
16. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
[TBL] [Abstract][Full Text] [Related]
17. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).
Stasi R; Del Poeta G; Venditti A; Masi M; Stipa E; Dentamaro T; Cox C; Dallapiccola B; Papa G
Blood; 1994 Mar; 83(6):1619-25. PubMed ID: 8123853
[TBL] [Abstract][Full Text] [Related]
18. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
19. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Handa H; Motohashi S; Isozumi K; Komatsumoto S; Nara M
Acta Haematol; 2002; 108(1):47-52. PubMed ID: 12145468
[TBL] [Abstract][Full Text] [Related]
20. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
